Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
77.94
+0.56 (0.73%)
Jul 30, 2025, 2:17 PM - Market open
Incyte Revenue
Incyte had revenue of $1.22B in the quarter ending June 30, 2025, with 16.46% growth. This brings the company's revenue in the last twelve months to $4.58B, up 18.87% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.58B
Revenue Growth
+18.87%
P/S Ratio
3.26
Revenue / Employee
$1,752,005
Employees
2,617
Market Cap
15.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INCY News
- 1 day ago - Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
- 1 day ago - Incyte lifts annual sales forecast for blood cancer drug after solid quarter - Reuters
- 1 day ago - Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire
- 5 days ago - Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 - Business Wire
- 20 days ago - Incyte to Report Second Quarter Financial Results - Business Wire
- 27 days ago - Incyte: New CEO Brings A New Possible Outcome - Seeking Alpha
- 27 days ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire